摘要
目的 探讨拉米夫定 (LAM )和迈普新 (胸腺肽α1、Tα1)两者联合治疗慢性乙型肝炎的近期疗效。方法 将 6 0例HBVDNA与HBeAg阳性的慢性乙型肝炎患者随机分成 2组Tα1+LAM组和LAM组。结果 治疗 2 6周后Tα1+LAM组血清HBeAg及HBVDNA转阴率为 70 % (2 1/30 )和 10 0 % (30 /30 )。明显高于LAM组 16 .7% (5 /30 )、83.3% (2 5 /30 )。治疗后ALT明显下降 ,治疗过程中未发现明显不良反应。结论 国产Tα1与LAM联合治疗慢性乙型肝炎 ,短期疗效明显优于单一应用LAM ,是安全、有效治疗慢性乙型肝炎的方法。
Objective To study the short-term curative effect of combination thymosin α 1(Tα 1) and lamivudine(LAM) for hepatitis B.Methods 60 patients who were positive HBVDNA and HBeAg were randomly divided into two groups:Tα 1 and LAM therapeutic group,and single LAM therapeutic group.Results After therapy 26 weeks,changing negative ratio of serum HBeAg and HBVDNA in Tα 1 and LAM therapeutic gaoup were 70%(21/30) and 100%(30/30) respectively,higher than that in LAM therapeutic group16.7%(5/30)and 83.3%(25/30) respectively,ALT descended significantly too.There were no obviously side effect in the courts of therapy.Conclusion China-made Tα 1 and LAM therapy for chronic hepatits B is a safe and effective plan,its short-term effect is significantly superior to single LAM therapy.
出处
《医药论坛杂志》
2004年第17期37-38,共2页
Journal of Medical Forum
